| Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice L Soucek, JR Whitfield, NM Sodir, D Massó-Vallés, E Serrano, ... Genes & development 27 (5), 504-513, 2013 | 347 | 2013 |
| Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis D Annibali, JR Whitfield, E Favuzzi, T Jauset, E Serrano, I Cuartas, ... Nature communications 5 (1), 4632, 2014 | 205 | 2014 |
| Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy ME Beaulieu, T Jauset, D Massó-Vallés, S Martínez-Martín, P Rahl, ... Science translational medicine 11 (484), eaar5012, 2019 | 189 | 2019 |
| Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma D Massó-Vallés, T Jauset, E Serrano, NM Sodir, K Pedersen, NI Affara, ... Cancer research 75 (8), 1675-1681, 2015 | 117 | 2015 |
| Blocking Myc to treat cancer: reflecting on two decades of omomyc D Massó-Vallés, L Soucek Cells 9 (4), 883, 2020 | 103 | 2020 |
| MYC, MYCL, and MYCN as therapeutic targets in lung cancer D Masso-Valles, ME Beaulieu, L Soucek Expert Opinion on Therapeutic Targets 24 (2), 101-114, 2020 | 85 | 2020 |
| Ibrutinib repurposing: from B-cell malignancies to solid tumors D Massó-Vallés, T Jauset, L Soucek Oncoscience 3 (5-6), 147, 2016 | 24 | 2016 |
| BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC T Jauset, D Massó-Vallés, S Martínez-Martín, ME Beaulieu, L Foradada, ... Oncotarget 9 (27), 18734, 2018 | 23 | 2018 |
| Pancreatic cancer heterogeneity and response to Mek inhibition K Pedersen, F Bilal, C Bernado Morales, MT Salcedo, T Macarulla, ... Oncogene 36 (40), 5639-5647, 2017 | 22 | 2017 |
| MYC inhibition halts metastatic breast cancer progression by blocking growth, invasion, and seeding D Massó-Vallés, ME Beaulieu, T Jauset, F Giuntini, MF Zacarías-Fluck, ... Cancer Research Communications 2 (2), 110-130, 2022 | 16 | 2022 |
| The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets MF Zacarías-Fluck, T Jauset, S Martínez-Martín, J Kaur, ... Life science alliance 4 (5), 2021 | 8 | 2021 |
| MYC targeting by OMO-103 in solid tumors: a phase 1 trial E Garralda, ME Beaulieu, V Moreno, S Casacuberta-Serra, ... Nature Medicine, 1-10, 2024 | 7 | 2024 |
| Pharmacokinetic analysis of omomyc shows lasting structural integrity and long terminal half-life in tumor tissue ME Beaulieu, S Martínez-Martín, J Kaur, V Castillo Cano, D Massó-Vallés, ... Cancers 15 (3), 826, 2023 | 5 | 2023 |
| 916 Modeling Pharmacological Inhibition of Bruton's Tyrosine Kinase (BTK) as a Therapy for Insulinoma and Pancreatic Ductal Adenocarcinoma L Soucek, D Masso-Valles, T Jauset, JR Whitfield, JJ Buggy, NM Sodir, ... european journal of cancer, S222, 2012 | 2 | 2012 |
| Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma MF Zacarías-Fluck, D Massó-Vallés, F Giuntini, Í González-Larreategui, ... Genes & Development 37 (7-8), 303-320, 2023 | 1 | 2023 |
| Methods of treating fibrosis TJ González, D Massó-vallés, L Soucek US Patent 10,226,466, 2019 | 1 | 2019 |
| Methods of treating fibrosis TJ Gonzá, D Massó-vallés, L Soucek US Patent 9,844,552, 2017 | 1 | 2017 |
| Pharmacological inhibition of Bruton's Tyrosine Kinase (BTK) as a therapy for insulinoma and pancreatic ductal adenocarcinoma. D Massó-Vallés, E Serrano, JR Whitfield, JJ Buggy, NM Sodir, NI Affara, ... Cancer Research 73 (8_Supplement), 4956-4956, 2013 | 1 | 2013 |
| Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue S Martínez Martín, V Castillo Cano, D Massó Vallés, S López-Estévez, ... MDPI, 2023 | | 2023 |
| MYC inhibition by OMO-103 induces immune cell recruitment in preclinical models of NSCLC and modulates the cytokine and chemokine profiles of Phase I patients showing stable … SC Serra, S Martínez-Martín, Í González-Larreategui, S López-Estévez, ... European Journal of Cancer 174, S46-S47, 2022 | | 2022 |
lsoucekPrincipal Investigator, Vall d'Hebron Institute of OncologyDirección de correo verificada de vhio.net
